Lourdes Maria Perez-Chada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1304648/publications.pdf

Version: 2024-02-01

36 papers

537 citations

1040056 9 h-index 713466 21 g-index

38 all docs 38 docs citations

38 times ranked 764 citing authors

#	Article	IF	CITATIONS
1	Coronary microvascular dysfunction in patients with psoriasis. Journal of Nuclear Cardiology, 2022, 29, 37-42.	2.1	18
2	Hepatitis B and C among patients with hidradenitis suppurativa: a populationâ€based study. International Journal of Dermatology, 2022, 61, 84-88.	1.0	3
3	Leveraging behavioral economics to promote treatment adherence: A primer for the practicing dermatologist. Journal of the American Academy of Dermatology, 2022, 87, 1075-1080.	1.2	4
4	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. Dermatology, 2022, 238, 430-437.	2.1	4
5	Physician Perspectives on the Effect of Topical Steroid Costs on Patients and Proposed Solutions. JAMA Dermatology, 2022, 158, 79.	4.1	4
6	Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature Review. Journal of Investigative Dermatology, 2022, 142, 2026-2029.e4.	0.7	0
7	Treatment of immune checkpoint inhibitor–mediated psoriasis: AÂsystematic review. Journal of the American Academy of Dermatology, 2022, 87, 399-400.	1.2	9
8	Increased prevalence of sleep disturbance in psoriatic arthritis is associated with inflammatory and non-inflammatory measures. Scandinavian Journal of Rheumatology, 2022, , 1-9.	1,1	6
9	Report of the Skin Research Working Groups from the GRAPPA 2021 Annual Meeting. Journal of Rheumatology, 2022, , jrheum.211328.	2.0	O
10	Measuring fatigue: a metaâ€review. International Journal of Dermatology, 2021, 60, 1053-1069.	1.0	26
11	Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM). Dermatology, 2021, 237, 151-157.	2.1	6
12	Low gene expression of TNF, IL17A, IL23A, and IL12B in tumors: A safety surrogate to predict cancer survival associated with biologic therapies. Journal of the American Academy of Dermatology, 2021, 85, 249-252.	1.2	2
13	Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. Nature Reviews Rheumatology, 2021, 17, 238-243.	8.0	23
14	Hidradenitis suppurativa odour and drainage scale: a novel method for evaluating odour and drainage in patients with hidradenitis suppurativa. British Journal of Dermatology, 2021, 184, 772-774.	1.5	4
15	Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory Disorders. JACC: Cardiovascular Imaging, 2021, 14, 2212-2220.	5.3	24
16	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. Journal of Rheumatology, 2021, , jrheum.201668.	2.0	8
17	Hidradenitis suppurativa and sleep disorders: a populationâ€based study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e520-e522.	2.4	6
18	The association between schizophrenia spectrum disorders and psoriasis: a largeâ€scale populationâ€based case–control study. British Journal of Dermatology, 2021, 185, 443-445.	1.5	2

#	Article	IF	CITATIONS
19	Development of a working core outcome set for cutaneous lupus erythematosus: a practical approach to an urgent unmet need. Lupus Science and Medicine, 2021, 8, e000529.	2.7	9
20	Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. Journal of the American Academy of Dermatology, 2020, 82, 54-61.	1.2	4
21	Report from the International Dermatology Outcome Measures Initiative. Journal of Investigative Dermatology Symposium Proceedings, 2020, 20, S80-S83.	0.8	1
22	Psoriasis and COVID-19: a multifactorial consideration. Journal of Dermatological Treatment, 2020, , 1-1.	2.2	2
23	Older adults on systemic treatment for psoriasis and risk of infection: a propensity scoreâ€matched populationâ€based study. British Journal of Dermatology, 2020, 183, 564-566.	1.5	5
24	Certolizumab-Induced Paradoxical Psoriatic Alopecia. Journal of Psoriasis and Psoriatic Arthritis, 2020, 5, 86-92.	0.7	1
25	The National Psoriasis Foundation psoriasis treatment targets in realâ€world patients: prevalence and association with patientâ€reported outcomes in the Corrona Psoriasis Registry. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2051-2058.	2.4	5
26	Measurement properties of instruments assessing psoriatic arthritis symptoms for psoriasis clinical trials: a systematic literature review. Expert Review of Clinical Immunology, 2020, 16, 267-283.	3.0	2
27	Investigator and Patient Global Assessment Measures for Psoriasis Clinical Trials: A Systematic Review on Measurement Properties from the International Dermatology Outcome Measures (IDEOM) Initiative. American Journal of Clinical Dermatology, 2020, 21, 323-338.	6.7	6
28	Patient Perspectives on the Use of Artificial Intelligence for Skin Cancer Screening. JAMA Dermatology, 2020, 156, 501.	4.1	135
29	Comorbidities associated with psoriatic arthritis: Review and update. Clinical Immunology, 2020, 214, 108397.	3.2	83
30	TNF Inhibitor-Induced Psoriasis: Proposed Algorithm for Treatment and Management. Journal of Psoriasis and Psoriatic Arthritis, 2019, 4, 70-80.	0.7	67
31	Report of the Skin Research Workgroups from the GRAPPA 2018 Annual Meeting. Journal of Rheumatology, 2019, 95, 28-32.	2.0	2
32	Psoriatic arthritis and the dermatologist: An approach to screening and clinical evaluation. Clinics in Dermatology, 2018, 36, 551-560.	1.6	15
33	Bridging the Gaps in the Care of Psoriasis and Psoriatic Arthritis: the Role of Combined Clinics. Current Rheumatology Reports, 2018, 20, 76.	4.7	22
34	Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. Archives of Dermatological Research, 2018, 310, 701-710.	1.9	10
35	Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis. Dermatology, 2018, 234, 157-165.	2.1	10
36	International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group. Journal of Drugs in Dermatology, 2017, 16, 770-777.	0.8	5